European Morning Report
SEE OTHER BRANDS

Your daily news update on Europe

European Morning Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Morning Report.

Press releases published on June 12, 2025

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritis Rapid onset of action observed Improvement in function out of proportion to pain-relieving effects First-in-class novel biologic …

Nokia and Elisa modernize network for Advanced 5G era

Nokia and Elisa modernize network for Advanced 5G era

Press Release Nokia and Elisa modernize network for Advanced 5G era Nokia to supply Advanced 5G (5.5G) ready solutions from its industry-leading AirScale portfolio supporting AI applications. Continued partnership will see Elisa and Nokia deploy cloud- …

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI)   $10 million …

SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer

SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer

COPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in its …

Amaroq lýkur vel heppnaðri hlutafjáraukningu

Amaroq lýkur vel heppnaðri hlutafjáraukningu

Reykjavík, June 12, 2025 (GLOBE NEWSWIRE) -- ÞESSI TILKYNNING OG UPPLÝSINGARNAR SEM HÉR BIRTAST ERU EKKI ÆTLAÐAR TIL ÚTGÁFU, BIRTINGAR EÐA DREIFINGAR, BEINT EÐA ÓBEINT, Í HEILD EÐA AÐ HLUTA, Í EÐA TIL BANDARÍKJANNA, ÁSTRALÍU, JAPAN, LÝÐVELDISINS SUÐUR- …

Results of Fundraising

Results of Fundraising

Reykjavík, June 12, 2025 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, …

Korean telco KT selects the Digital Vending Machine® from Bango to power next-gen subscription bundles

Korean telco KT selects the Digital Vending Machine® from Bango to power next-gen subscription bundles

CAMBRIDGE, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Bango PLC (AIM:BGO, OTCQX:BGOPF), the leader in subscription bundling, today announces a strategic partnership with KT, a leading telecommunications provider in the Republic of Korea, to deliver …

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY …

AB Science annonce la délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloide aigue, avec une protection jusqu’à 2036

AB Science annonce la délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloide aigue, avec une protection jusqu’à 2036

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE LA DÉLIVRANCE D'UN BREVET CANADIEN PROTÉGEANT LA COMPOSITION DE MATIERE D’AB8939, Y COMPRIS SON UTILISATION DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË (LMA), AVEC UNE PROTECTION JUSQU'EN 2036 CE BREVET COMPLÈTE …

Aalberts N.V.: Aalberts successfully issues US Private Placement of USD 600 million

Aalberts N.V.: Aalberts successfully issues US Private Placement of USD 600 million

Utrecht, 12 June 2025 Aalberts announces the successful signing and closing of Note Purchase Agreements for its inaugural debt issuance in the US Private Placement (USPP) market, securing a total equivalent amount of approximately USD 600 million. The …

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

US-based Dieter Weinand is the former CEO of Bayer Pharma with more than 25 years of experience as a senior business leader in the pharmaceutical industry The appointment comes as AstriVax Therapeutics matures as a clinical stage immunotherapy company with …

Critical One Makes Strategic Uranium Asset Divestment

Critical One Makes Strategic Uranium Asset Divestment

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that Dark Star Minerals Inc. (“Dark Star”) (CSE: BATT) (FSE: …

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) …

Solver99.com now Enables User Tracking Through Comprehensive Transaction Reports

Solver99.com now Enables User Tracking Through Comprehensive Transaction Reports

LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- Solver99.com is a provider of financial services that supports transaction monitoring through simple financial tools. The focus remains on helping users manage financial records with clarity. By using reporting …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions